Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2571-2580 Newer>

The Motley Fool December 13, 2005 Stephen D. Simpson	Take a Good, Long Look at Cooper Tough competition is eating away at the contact lens maker's growth. This is a stock that could require an above-average level of patience and tolerance for risk in the meantime.
The Motley Fool December 12, 2005 Stephen D. Simpson	Heavy Breathing for Myogen Positive data from a phase 3 drug study sends shares of this biotech much higher.
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
BusinessWeek December 19, 2005 Gene G. Marcial	A German Feather In Sonus' Cap Institutional investors weren't privy to what tiny biotech Sonus Pharmaceuticals was up to, but the German giant Schering AG knew -- and acted.
The Motley Fool December 8, 2005 Tom Taulli	MedAvant Name Not All That's New The company used to be ProxyMed, and its new CEO is serious about making changes.
The Motley Fool December 6, 2005 Stephen D. Simpson	Tysabri Tries Again Will the FDA finally approve Elan's multiple sclerosis drug? Investors' fingers are crossed.
Pharmaceutical Executive December 1, 2005 Grant Winter	Inside DDMAC: A Conversation with Thomas Abrams Despite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says the director of FDA's Division of Drug Marketing, Advertising, and Communications.
Pharmaceutical Executive December 1, 2005 Meg Columbia-Walsh	Direct to Consumer: Culturally Relevant Marketing Through culturally relevant marketing, pharma can seamlessly weave its brands into consumers' lives... Also: The 2005 Pharmaceutical Advertising and Marketing Excellence Award recipients...
Pharmaceutical Executive December 1, 2005 Larry Star	Marketing to Professionals: Appealing to Doctor's Emotions Borrowing from the disciplines of cognitive psychology and cultural anthropology, marketers can identify the emotional triggers that will evoke feeling and empathy in medical specialists, helping to overcome a doctor's initial resistance to a new product or concept.
Pharmaceutical Executive December 1, 2005 Jill Wechsler	Washington Report: Big Production Drug manufacturing costs too much and is cumbersome to regulate. FDA's answer: Quality by design, which shifts the emphasis from testing the final product to building quality into the manufacturing process from the beginning.
<Older 2571-2580 Newer> Return to current articles.